NGHIÊN CỨU VAI TRÒ CỦA THUỐC CHỐNG VIÊM BROMFENAC TRONG DỰ PHÒNG PHÙ HOÀNG ĐIỂM DẠNG NANG SAU PHẪU THUẬT PHACO THỂ THỦY TINH (PCME)

Abstract

Objective: Studying the role of the anti-inflamatory drug bromfenac for preventing pseudophakic cystoid macular edema. Method : Prospective descriptive study on 184 eyes after phacoemulsification, then, evaluate the role of the anti-inflammatory drug Bronuck 0.1% (bromfenac 0.1%) by monitoring CST, CV, CAT indicators on Optical Tomography Machine Cirrus HD –OCT 5000 through the time points before surgery, 1 week, 5 weeks, 9 weeks after surgery from October 2021 to the end of August 2022 at Ha Dong Eye Hospital. Results : Bronuck's ability to prevent cystic macular edema (Bromfenac 0.1%) in combination with topical dexamethasone was better than with dexamethasone as local monotherapy with morbidity rates of 0% in the Bromfenac + Dexamethasone group and 2.2% in the dexamethasone monotherapy group. Change in CST in the group adding Bromfenac 2.97 ± 23.48, 1.5 ± 10.25 µm was better than with Decamethasone alone, 15.60 ± 39.77, 13.2 ± 40.5 µm at 5 weeks, 9 weeks after surgery with p < 0.05. The degree of visual acuity improvement compared with the 5 weeks and 9 weeks is equivalent to p of 0.25 and 0.745, respectively. Bromfenac+ Dexamethasone is 0.5699 ± 0.2327 and 0.5772 ±0.2396 LogMAR; Dexamethasone alone 0.5872 ± 0.2236 and 0.5897 ± 0.2257 LogMAR. Conclusion: Using OCT as a non-invasive, reliable and safe subclinical means allows us to detect, diagnose, monitor, and treat cystic macular edema (PCME). Using Bromfenac solution combined with Dexamethasone has a better effect on prevention of cystic macular edema than Dexamethasone monotherapy.